Beyond pain: The surprising connection between tramadol and depression
Abstract
Background: Tramadol, a centrally acting analgesic with a dual mechanism, is frequently prescribed for pain management, including in cancer patients. However, its association with depression, a multifactorial condition influenced by genetic, biochemical, environmental, and psychosocial factors, requires further elucidation. Objective: This study aims to investigate the potential link between tramadol exposure and depression through a comprehensive analysis of pharmacovigilance data and Mendelian randomization methods. Methods: We conducted a retrospective analysis using the FDA Adverse Event Reporting System (FAERS) database, focusing on reports from Q1 2004 to Q1 2023. Data from the EBI and UK Biobank databases were also utilized. Disproportionate analysis methods, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN), were applied to evaluate the relationship between tramadol and depression. Mendelian randomization was performed using the “TwoSampleMR” package in R software to assess the causal relationship. Results: The pharmacovigilance analysis revealed that mental disorders were the most frequently reported adverse events associated with tramadol use, with a significant positive association between tramadol and depression reports (ROR 1.34, 95% CI 1.25–1.44; PRR 1.34, 95% CI 1.26–1.43). Mendelian randomization analysis indicated a significant positive correlation between tramadol exposure and depression (P (IVW) = 0.01). At the same time, our comparative analysis of the risk of depression between tramadol and other opioids found that tramadol was more associated with depression risk than other opioids. Multivariate Mendelian randomization results showed that a causal relationship between tramadol and depression remained when chronic pain was considered an important confounder. Conclusion: The association between tramadol use and depression has significant clinical implications for patient safety and the optimization of treatment strategies. Future research should explore the impact of tramadol on the neurotransmitter system and its efficacy and safety in different subpopulations of patients with depression.
References
Thapar A, Eyre O, Pate V, et al. Depression in young people. The LANCET. 2022; 400(10352): 617-631. doi: 10.1016/S0140-6736(22)01012-1
Abdel Shaheed C, Hayes C, Maher CG, et al. Opioid analgesics for nociceptive cancer pain: A comprehensive review. CA: A Cancer Journal for Clinicians. 2023; 74(3): 286-313. doi: 10.3322/caac.21823
Agnoli A, Xing G, Tancredi DJ, et al. Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids. JAMA. 2021; 326(5): 411. doi: 10.1001/jama.2021.11013
Bravo L, Mico JA, Berrocoso E. Discovery and development of tramadol for the treatment of pain. Expert Opinion on Drug Discovery. 2017; 12(12): 1281-1291. doi: 10.1080/17460441.2017.1377697
Hsu SK, Yeh CC, Lin CJ, et al. An open label trial of the effects and safety profile of extended-release tramadol in the management of chronic pain. Acta Anaesthesiologica Taiwanica. 2012; 50(3): 101-105. doi: 10.1016/j.aat.2012.08.008
Von Dohlen M, Jones J. Chronic use of tramadol after acute pain episode: cohort study. The Journal of Emergency Medicine. 2019; 57(4): 595. doi: 10.1016/j.jemermed.2019.08.050
Browne CJ, Godino A, Salery M, et al. Epigenetic Mechanisms of Opioid Addiction. Biological Psychiatry. 2020; 87(1): 22-33. doi: 10.1016/j.biopsych.2019.06.027
Ito H, Navratilova E, Vagnerova B, et al. Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. Brain. 2022; 146(3): 1186-1199. doi: 10.1093/brain/awac153
Hioki T, Tokuda H, Tanabe K, et al. Amplification by tramadol of PGD2-induced osteoprotegerin synthesis in osteoblasts: Involvement of μ-opioid receptor and 5-HT transporter. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2021; 172: 102323. doi: 10.1016/j.plefa.2021.102323
Talbot JN, Jutkiewicz EM, Graves SM, et al. RGS inhibition at Gα i2 selectively potentiates 5-HT1A–mediated antidepressant effects. Proceedings of the National Academy of Sciences. 2010; 107(24): 11086-11091. doi: 10.1073/pnas.1000003107
Lin S, Lei S, Liu W, et al. Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study. International Journal of Clinical Pharmacy. 2024; 46(5): 1076-1090. doi: 10.1007/s11096-024-01738-6
Mukamal KJ, Stampfer MJ, Rimm EB. Genetic instrumental variable analysis: time to call mendelian randomization what it is. The example of alcohol and cardiovascular disease. European Journal of Epidemiology. 2019; 35(2): 93-97. doi: 10.1007/s10654-019-00578-3
Chen K, Huang H, Chen Y, et al. Association between atorvastatin and erectile dysfunction: a comprehensive analysis incorporating real-world pharmacovigilance and Mendelian randomization. Frontiers in Pharmacology. 2024; 15. doi: 10.3389/fphar.2024.1382924
Zhao B, Zhang X, Chen M, et al. A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database. Expert Opinion on Drug Metabolism & Toxicology. 2023; 19(6): 381-387. doi: 10.1080/17425255.2023.2235267
Shu Y, He X, Liu Y, et al. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System. Clinical Epidemiology. 2022; 14: 789-802. doi: 10.2147/clep.s365513
van Puijenbroek EP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety. 2002; 11(1): 3-10. doi: 10.1002/pds.668
Yang H, Wan Z, Chen M, et al. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database. Expert Opinion on Drug Metabolism & Toxicology. 2023; 19(4): 217-223. doi: 10.1080/17425255.2023.2219390
Zagkos L, Dib MJ, Pinto R, et al. Associations of genetically predicted fatty acid levels across the phenome: A mendelian randomisation study. Ma RCW, ed. PLOS Medicine. 2022; 19(12): e1004141. doi: 10.1371/journal.pmed.1004141
Wang S, Zhu H, Pan L, et al. Systemic inflammatory regulators and risk of acute-on-chronic liver failure: A bidirectional mendelian-randomization study. Frontiers in Cell and Developmental Biology. 2023; 11. doi: 10.3389/fcell.2023.1125233
Chen X, Kong J, Diao X, et al. Depression and prostate cancer risk: A Mendelian randomization study. Cancer Medicine. 2020; 9(23): 9160-9167. doi: 10.1002/cam4.3493
Arnold M, Raffler J, Pfeufer A, et al. SNiPA: an interactive, genetic variant-centered annotation browser. Bioinformatics. 2014; 31(8): 1334-1336. doi: 10.1093/bioinformatics/btu779
Chen S, Sun H, Song Y, et al. Transition and trend analysis of the burden of depression in China and different income countries: Based on GBD database and joinpoint regression model. Journal of Affective Disorders. 2024; 362: 437-449. doi: 10.1016/j.jad.2024.06.067
Rogers AH, Orr MF, Shepherd JM, et al. Anxiety, depression, and opioid misuse among adults with chronic pain: the role of emotion dysregulation. Journal of Behavioral Medicine. 2020; 44(1): 66-73. doi: 10.1007/s10865-020-00169-8
Tumenta T, Ugwendum DF, Chobufo MD, et al. Prevalence and Trends of Opioid Use in Patients With Depression in the United States. Cureus; 2021.
Barton MK. First‐line low‐dose morphine is better for the control of moderate cancer pain than weaker opioids. CA: A Cancer Journal for Clinicians. 2016; 66(3): 177-178. doi: 10.3322/caac.21303
Valian N, Sorayya M, Asadi S, et al. Preconditioning by ultra-low dose of tramadol reduces the severity of tramadol-induced seizure: Contribution of glutamate receptors. Biomedicine & Pharmacotherapy. 2021; 133: 111031. doi: 10.1016/j.biopha.2020.111031
Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Archives of Toxicology. 2018; 92(8): 2457-2473. doi: 10.1007/s00204-018-2244-6
Bravery B, Loughnan S, Murphy M. Depression treatment research in people with cancer does not reflect cancer prevalence: findings from a systematic review. Evidence Based Mental Health. 2020; 23(4): 155-160. doi: 10.1136/ebmental-2020-300145
Panjwani AA, Aguiar S, Gascon B, et al. Biomarker opportunities in the treatment of cancer-related depression. Trends in Molecular Medicine. 2022; 28(12): 1050-1069. doi: 10.1016/j.molmed.2022.10.003
Marinovic DA, Hunter RL. Examining the interrelationships between mindfulness‐based interventions, depression, inflammation, and cancer survival. CA: A Cancer Journal for Clinicians. 2022; 72(5): 490-502. doi: 10.3322/caac.21733
Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. British Journal of Anaesthesia. 2020; 124(1): 44-62. doi: 10.1016/j.bja.2019.08.010
Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic Psychiatry’s Brave New World. Cell. 2020; 181(1): 24-28. doi: 10.1016/j.cell.2020.03.020
Asari Y, Ikeda Y, Tateno A, et al. Acute tramadol enhances brain activity associated with reward anticipation in the nucleus accumbens. Psychopharmacology. 2018; 235(9): 2631-2642. doi: 10.1007/s00213-018-4955-z
Zhao F, Cheng Z, Piao J, et al. Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression? Frontiers in Pharmacology. 2022; 13. doi: 10.3389/fphar.2022.947785
Franceschini D, Lipartiti M, Giusti P. Effect of acute and chronic tramadol on [3H]-norepinephrine-uptake in rat cortical synaptosomes. Prog Neuropsychopharmacol Biol Psychiatry. 1999; 23 (3): 485-96. doi: 10.1016/S0278-5846(99)00010-X
Hosseindoost S, Akbarabadi A, Sadat‐Shirazi M, et al. Effect of tramadol on apoptosis and synaptogenesis in hippocampal neurons: The possible role of µ‐opioid receptor. Drug Development Research. 2022; 83(6): 1425-1433. doi: 10.1002/ddr.21973
Hare BD, Duman RS. Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions. Molecular Psychiatry. 2020; 25(11): 2742-2758. doi: 10.1038/s41380-020-0685-9
Shalaby AM, Aboregela AM, Alabiad MA, et al. Tramadol Promotes Oxidative Stress, Fibrosis, Apoptosis, Ultrastructural and Biochemical alterations in the Adrenal Cortex of Adult Male Rat with Possible Reversibility after Withdrawal. Microscopy and Microanalysis. 2020; 26(3): 509-523. doi: 10.1017/s1431927620001397
Xia W, Liu G, Shao Z, et al. Toxicology of tramadol following chronic exposure based on metabolomics of the cerebrum in mice. Scientific Reports. 2020; 10(1). doi: 10.1038/s41598-020-67974-8
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
